The “Cyagen Trailblazer Grant Award” (“Contest”) is open to academic, industry, and non-profit research professionals globally, including graduate students, post-doctoral researchers, principal investigators (PIs), staff scientists, and R&D professionals in the biotechnology and pharmaceutical industries who submit a complete application form at the official CTGA Campaign webpage.
To be eligible, applicants must have published at least one article in the past two (2) years in a peer-reviewed scientific journal with an impact factor greater than 20. Applicants must be at least eighteen (18) years of age as of the date of submission.
This Contest is subject to all applicable international, federal, and local laws and regulations and is void where prohibited. Employees of Cyagen, its affiliates, subsidiaries, advertising/promotional agencies, and their immediate family members or household members are not eligible.
The Contest is sponsored by Cyagen Biosciences, headquartered at 2255 Martin Ave, Suite E, Santa Clara, CA 95050, USA (“Sponsor”). The Contest is organized and supported according to the terms outlined in these Official Rules.
By participating, you agree to be fully and unconditionally bound by these Official Rules and the Sponsor’s decisions, which are final and binding in all matters related to this Contest. The Sponsor reserves the right to disqualify any participant who violates the Official Rules or acts in an unsportsmanlike or disruptive manner.
The Contest begins on August 15, 2025 at 12:01 AM (PST) and ends on September 30, 2025 at 11:59 PM (PST) (“Entry Period”). Applications submitted outside this period will not be accepted. Award announcements are scheduled for October 16, 2025.
Applicants must complete and submit the online application form available at the official CTGA Campaign webpage. A complete entry includes:
- Full name and contact details
- Affiliation and job title
- Area of disease research focus
- Type of model needed
- Publication Record (required): Provide the DOI or link to one peer-reviewed article (past 2 years, IF >20)
- A brief research summary outlining the scientific rationale and innovation
Only one application per lab or project will be accepted. Incomplete or non-compliant entries will be disqualified at the Sponsor’s sole discretion.
Up to 50 grant awards will be issued globally. Each award will provide 50%–100% funding coverage for the cost of developing a custom animal model using Cyagen’s services. The total award pool is up to $1,000,000 USD.
- Grant recipients must initiate the project within 6 months of notification unless an extension is pre-approved.
- The grant may only be applied to one model generation project, as defined in the submitted application.
- The award cannot be combined with other discounts or promotions.
- No cash alternative or prize substitution is permitted, except at the sole discretion of the Sponsor.
Recipients are responsible for any taxes or fees associated with the award. Execution of a service agreement is required prior to project start.
All models generated under the CTGA program (“Models”) are subject to the following terms:
- Ownership: The resulting animal models and associated technologies are jointly owned by the recipient and Sponsor.
- Usage Rights: The recipient is granted a 1-year exclusive usage period starting from model delivery.
- Non-commercial Use: Models may only be used for academic or non-commercial research purposes. No third-party transfers or commercial use is permitted without written authorization.
- Data Sharing: All downstream validation data produced using the Models must be shared with Cyagen and may be used by Cyagen for CRO services, publications, or promotional purposes, unless otherwise agreed.
Applications will be reviewed by a panel of scientific experts appointed by the Sponsor. Proposals will be evaluated based on:
- Scientific merit and innovation
- Clarity of research goals
- Fit between the proposed study and model type
- Feasibility and timeline
- Potential scientific or translational impact
Winners will be notified via email by October 16, 2025. Cyagen will not be responsible for undelivered messages due to spam filters or incorrect contact information. Failure to respond within 10 days may result in forfeiture.
By entering, you agree that Sponsor may use your name, institutional affiliation, and submitted content for promotional and marketing purposes, including but not limited to: press releases, presentations, or web content, without further compensation, unless prohibited by law.
Sponsor reserves the right to cancel, suspend, or modify the Contest at any time due to technical issues, fraud, or any other cause that corrupts the administration of the Contest. Any attempts to tamper with or undermine the entry process will result in disqualification.
By participating, entrants agree to release and hold harmless Cyagen and its affiliates from any and all claims arising from participation in the Contest or use of any awarded prize, including but not limited to personal injury, death, or property damage.
This Contest is governed by the laws of the State of California. All disputes arising under or related to the Contest shall be resolved individually, without resort to class action, and exclusively in the state or federal courts located in California.
All applicant information is confidential and will only be shared with Cyagen’s internal review
panel. Submission is subject to Cyagen’s
To request the list of grant recipients, contact: [email protected]
By submitting an entry, you acknowledge that you have read, understood, and agree to be bound by these Official Rules.
Cyagen Trailblazer Grant Award(CTGA)는 새로운 맞춤형 동물 모델을 개발하여 생의학 연구의 혁신을 가속하기 위해 설계된 글로벌 연구 지원 프로그램입니다. 복잡한 질환 발병 기전을 탐구하거나 신약 후보의 타겟을 검증하는 등, CTGA 프로그램은 연구를 더 빠르게 진전시킬 수 있도록 필요한 지원을 제공합니다.
2025년 Cyagen에서는 전 세계 50개 연구팀에 총 100만 달러($1,000,000) 규모의 모델 제작 연구비를 지원하며, 다음과 같은 다양한 연구 분야를 포함합니다.
연구 제안을 제출하고, 전임상 연구의 미래를 선도하는 글로벌 혁신 커뮤니티에 참여해 보세요.
전 세계 생명과학 분야 전문가들의 신청을 환영합니다. CTGA 프로그램 초대 대상에는 다음이 포함됩니다.
● 연구책임자(Principal Investigators) 및 연구실장(Lab Heads)
● 박사후 연구원 및 대학원생
● 학계, 산업계, 비영리 및 중개 연구팀
● 전임상 연구를 위해 맞춤형 동물 모델 사용을 계획 중인 연구원
신청 자격 안내:
지원자는 최근 2년 이내에 임팩트 팩터(Impact Factor)가 20 이상인 Peer-reviewed (심사 기반) 과학 저널에 최소 1편 이상의 논문을 게재한 경력이 있어야 합니다.
CTGA 프로그램은 종양학(Oncology), 신경과학(Neuroscience), 면역학(Immunology), 대사 질환(Metabolic Diseases), 희귀 질환(Rare Diseases), 심혈관 연구(Cardiovascular Research) 등 다양한 연구 분야를 포함하며, 해당 분야 연구원의 적극적인 참여를 환영합니다.
선정된 각 제안서는 다음과 같은 혜택을 받을 수 있습니다.
※ CTGA 프로그램이 제공하는 혜택은 다른 할인, 프로모션 등 혜택과 중복으로 적용할 수 없습니다.
※ 신청서는 Cyagen 과학 심사위원단에 의해 순차적으로 심사되므로, 가능한 빨리 제출하시면 선정 가능성이 높아집니다.
Cyagen은 맞춤형 동물 모델 제작 분야에서 세계적으로 선도적인 기업으로, 전 세계 7,000개 이상의 기관에서 신뢰받고 있습니다. Cyagen의 과학 기술 플랫폼은 광범위한 치료 영역에서 전임상 연구를 지원합니다.
다음에 표시된 Cyagen의 서비스를 통해 연구를 지원받을 수 있습니다.
관심 있는 주제를 클릭하시면 최신 데이터를 확인할 수 있습니다.
- ● 학술지: Nature
- ● 주제: Extreme resilience to autosomal dominant Alzheimer’s disease
- ● 사용 모델: RELN-H3447R-Tg
- ● 사용 모델: Researchers reported the second known case of “extreme resilience” to autosomal dominant Alzheimer’s disease (ADAD). The patient carried the PSEN1-E280A mutation but developed only mild cognitive impairment at age 67, despite a very high amyloid plaque burden. A rare gain-of-function variant, RELN-COLBOS, was found to enhance Dab1 activation and reduce Tau phosphorylation, suggesting that the Reelin signaling pathway can confer resistance to dementia.
- ● 학술지: Nature
- ● 주제: IL-4 signaling drives immunosuppressive myelopoiesis in cancer
- ● 사용 모델: Il4ra conditional knockout (S-CKO-03105)
- ● 하이라이트: This study uncovered IL-4 as a key regulator of pro-tumorigenic myeloid cell development in the bone marrow, primarily secreted by basophils and eosinophils. Deletion of IL-4Rα in early myeloid progenitors reduced tumor burden in mice, whereas deletion in mature myeloid cells had no effect. A clinical trial combining IL-4Rα blockade (dupilumab) with PD-1/PD-L1 checkpoint inhibitors in NSCLC patients showed promising responses, including near-complete remission in one patient.
- ● 학술지: European Heart Journal
- ● 주제: Eosinophil proteins promote vascular calcification
- ● 사용 모델: Bmpr1b conditional knockout (S-CKO-01441)
- ● 하이라이트: Eosinophil-derived proteins (mEar1, ECP, EDN) bind to BMPR-1A/1B receptors on vascular smooth muscle cells, activating the BMPR-1A/1B–Smad-1/5/8–Runx2 signaling pathway. This drives osteogenic differentiation and vascular calcification. In a 5,864-participant cohort from the DANCAVAS trial, eosinophil counts correlated with arterial calcification scores. Mouse models confirmed causality through knockout and adoptive transfer experiments.
- ● 학술지: Nature
- ● 주제: Matrix-producing neutrophils protect skin integrity
- ● 사용 모델: Col3a1-CKO, Rosa26LSL; CNA35-mCherry
- ● 하이라이트: A newly identified population of neutrophils can produce extracellular matrix proteins, forming protective “rings” around wounds. This structural defense depends on TGFβ signaling, and disabling TGFβ receptors in neutrophils compromised barrier function and increased bacterial invasion risk.
- ● 학술지: Nature
- ● 주제: CUL2-APPBP2 E3 ligase regulates PRDM16 stability and beige fat biogenesis
- ● 사용 모델: Appbp2 conditional knockout (S-CKO-17610)
- ● 하이라이트: CUL2-APPBP2 promotes PRDM16 degradation, suppressing beige fat formation and thermogenesis. Using the protein neddylation inhibitor MLN4924, researchers confirmed CUL2 as the cullin-RING family member responsible for PRDM16 ubiquitination. Inhibition of this pathway enhanced PRDM16 stability, improved glucose tolerance, reduced obesity, and reversed insulin resistance in mouse models.
번거로운 연구비 제안서 작성할 필요 없이, 아래 간단한 양식을 작성하여 CTGA 프로그램에 참여 신청을 하실 수 있습니다.
(예: 과학적 근거, 핵심 연구 질문, 혁신적인 측면)
- 공인된 학술 기관 또는 비영리 연구 기관에 소속되는 18세 이상인 연구원이 CTGA 프로그램에 신청할 수 있습니다.
- 선정된 연구 프로젝트는 수상일로부터 6개월 이내에 시작되어야 합니다.
- 수상자는 Cyagen과 연구 모델 제작 계약(Model Generation Agreement)을 체결하고 Cyagen 공식 콘테스트 규칙에 동의하신 것으로 간주합니다.
- 선정된 프로젝트의 연구 모델은 Cyagen과 공동 소유되며, 수상자는 모델 인도일로부터 1년간 독점 사용권을 가집니다.
- 해당 실험용 모델은 연구 목적에만 사용할 수 있으며, 재판매, 라이선스 제공 또는 제3자 배포는 금지됩니다.
